Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Stéphane Bancel

Moderna Q3 2025 Earnings Call Transcript

Moderna, Inc (NASDAQ:MRNA) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below. MRNA is building positive momentum. Watch the momentum here This transcript is brought to you by Benzinga APIs. For real-time access to our entire catalog, please visithttps://www.benzinga.com/apis/for a consultation. Operator…

Benzinga

Moderna boss defends UK in drug-pricing row as he opens £150m Oxfordshire facility

‘We’re here to invest,’ says Darius Hughes as he calls comments by other pharma companies ‘a little harsh’

The Guardian - UK

Moderna Loses $700M US Contract for Bird Flu Vaccine Development

Moderna loses $700 million U.S. contract to develop bird flu vaccine after government review ends funding.

International Business Times

From analysis to the latest developments in health,
read the most diverse news in one place.

Moderna Is the Largest of Barchart’s Bottom 100 Stocks to Buy—But Size Alone Isn’t a Reason to Invest

Moderna is the largest market cap in Barchart’s Bottom 100 Stocks to Buy. On Monday, the vaccine maker moved seven spots to the 86th position. You don’t want to make this list if you are the CEO. Here’s why.

Barchart

Moderna Stock Plunges as Vaccine Maker Slashes R&D Budget: What to Know

Moderna stock is plunging Thursday after the COVID-19 vaccine maker announced plans to drastically cut its R&D spending to focus on new product approvals.

Kiplinger

Moderna signs deal to make mRNA vaccines for Chinese market

Moderna Inc. will push toward producing messenger RNA vaccines for China, seeking a foothold in the world’s second-largest pharmaceutical market even as geopolitical tensions rise.

Tribune News Service

U.S. inaction on A.I. regulation leaves EU to take the lead

The EU's draft A.I. Act is poised to become law.

Fortune

Read news from The Economist, FT, and more,
with one subscription

Sen. Bernie Sanders shows fire, but seeks modest goals, in his debut drug hearing as health chair

Sen. Bernie Sanders, who rose to national prominence criticizing big business in general and the pharmaceutical industry in particular, claimed the spotlight Wednesday on what might at first seem a powerful new stage from which to advance his agenda: chairmanship of the Senate health committee.

Tribune News Service

Michael Hiltzik: Biden says he wants to bring down drug prices. His actions tell a different story

You might get the impression from the Biden administration's insulin price cut and its initiative allowing Medicare to negotiate over other pharmaceuticals that the drug pricing issue is finally being taken seriously in Washington.

Los Angeles Times

Moderna CEO grilled by Senate panel over planned price hike

WASHINGTON — Moderna CEO Stéphane Bancel attempted on Wednesday to win over lawmakers irate about the company’s planned COVID-19 vaccine price increase, weathering a barrage of criticism from Democrats angry at the company’s profits from its groundbreaking mRNA vaccine.

Tribune News Service

Moderna CEO grilled by Senate panel over planned price hike - Roll Call

In a Senate hearing, Moderna's CEO tried to soothe lawmakers angry about plans to increase the cost of COVID-19 vaccines.

Roll Call

Moderna's COVID vaccine gambit: Hike the price, offer free doses for uninsured

Once U.S. stockpiles of COVID-19 vaccine run out, Moderna says it might charge as much as $130 per dose, but give people who lack health insurance a break. Critics say that's not enough help.

WEKU

Moderna won’t raise price on COVID vaccine after pressure

Moderna said Wednesday it wouldn’t raise the price of its COVID-19 vaccine after a public outcry.

Tribune News Service

Michael Hiltzik: Moderna and Pfizer are jacking up the price of COVID vaccines. The government should stop them

Stéphane Bancel, the chief executive of drug company Moderna, could barely restrain his pride in issuing his annual letter to shareholders on Jan. 3.

Los Angeles Times

Get all your
news in one place.

100’s of premium titles.
One news app.

Mic

Researchers from Moderna and Merck just made a breakthrough with a skin cancer vaccine

Thank you, science.

Axios

Moderna booster update for Omicron variant could be available late summer

The booster contains the original vaccine with an updated version that specifically targets the Omicron variant.

Bangkok Post

Median CEO Pay Package Rose to $14.7 Million in 2021, a New High

The median pay package for chief executives of the biggest U.S. companies reached $14.7 million in 2021, setting a sixth-straight annual record as strong profits and robust markets boosted performance measures.

Roll Call

Moderna asks FDA to authorize COVID-19 vaccine for kids under 6 - Roll Call

Moderna said Thursday that it asked the FDA for emergency use authorization of its COVID-19 vaccine in kids under age 6.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

mRNA Vaccine Maker CEOs Pocketed $100M In Pandemic Pay: FT

The CEOs of Pfizer Inc (NYSE: PFE), BioNTech SE (NASDAQ: BNTX), and Moderna Inc (NASDAQ: MRNA) have sha

Benzinga

Here's Why Moderna Shares Are Rising

Moderna Inc (NASDAQ: MRNA) shares are trading higher by 4.67% at $181.16 after the company received FDA approval for Emergency Use Authorization for a second booster dose of its COVID-19 vaccine.

Benzinga

Health Canada Approves Moderna's COVID-19 Vaccine For Kids Aged 6-11 Years

Health Canada has approved Moderna Inc's (NASDAQ:MRNA) mRNA COVID-19 vaccine, Spikevax, two-dose series of 50 µg per dose to prevent COVID-19 in children aged six to11 years. The announcement follows the recent authorization of the Company's COVID-19 vaccine in the same age group in both Australia and the European Union. "Health Canada was…

Benzinga

Moderna CEO Sells Shares, Deletes Social Media: What You Need To Know

Moderna Inc (NASDAQ: MRNA) shares are down more than 40% since the start of the year and continue to trend lower Monday.

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.